Requirement for cyclin D3 in lymphocyte development and T cell leukemias

被引：278

作者：

Sicinska, E

Aifantis, L

Le Cam, L

Swat, W

Borowski, C

Yu, QY

Ferrando, AA

Levin, SD

Geng, Y

von Boehmer, H

Sicinski, P ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA

[4] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA

[5] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA

[6] Univ Chicago, Dept Med, Chicago, IL 60637 USA

[7] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA

[8] Univ Washington, Dept Immunol, Seattle, WA 98195 USA

来源：

CANCER CELL | 2003年 / 4卷 / 06期

关键词：

D O I：

10.1016/S1535-6108(03)00301-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The D-type cyclins (cyclins D1, D2, and D3) are components of the core cell cycle machinery in mammalian cells. Cyclin D3 gene is rearranged and the protein is overexpressed in several human lymphoid malignancies. In order to determine the function of cyclin D3 in development and oncogenesis, we generated and analyzed cyclin D3-deficient mice. We found that cyclin D3(-/-) animals fail to undergo normal expansion of immature T lymphocytes and show greatly reduced susceptibility to T cell malignancies triggered by specific oncogenic pathways. The requirement for cyclin D3 also operates in human malignancies, as knock-down of cyclin D3 inhibited proliferation of acute lymphoblastic leukemias deriving from immature T lymphocytes. These studies point to cyclin D3 as a potential target for therapeutic intervention in specific human malignancies.

引用

页码：451 / 461

页数：11

共 62 条

[21] CRUCIAL ROLE OF THE PRE-T-CELL RECEPTOR-ALPHA GENE IN DEVELOPMENT OF ALPHA-BETA BUT NOT GAMMA-DELTA T-CELLS
FEHLING, HJ
KROTKOVA, A
SAINTRUF, C
VONBOEHMER, H
[J]. NATURE, 1995, 375 (6534) : 795 - 798
[22] Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
Ferrando, AA
Neuberg, DS
Staunton, J
Loh, ML
Huard, C
Raimondi, SC
Behm, FG
Pui, CH
Downing, JR
Gilliland, DG
Lander, ES
Golub, TR
Look, AT
[J]. CANCER CELL, 2002, 1 (01) : 75 - 87
[23] Filipits M, 2002, CLIN CANCER RES, V8, P729
[24] Cyclin D1 amplification correlates with early recurrence of squamous cell carcinoma of the tongue
Fujii, M
Ishiguro, R
Yamashita, T
Tashiro, M
[J]. CANCER LETTERS, 2001, 172 (02) : 187 - 192
[25] Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
Golub, TR
Slonim, DK
Tamayo, P
Huard, C
Gaasenbeek, M
Mesirov, JP
Coller, H
Loh, ML
Downing, JR
Caligiuri, MA
Bloomfield, CD
Lander, ES
[J]. SCIENCE, 1999, 286 (5439) : 531 - 537
[26] Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor - Study of Lck- and FynT-dependent T cell activation
Hanke, JH
Gardner, JP
Dow, RL
Changelian, PS
Brissette, WH
Weringer, EJ
Pollok, K
Connelly, PA
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (02) : 695 - 701
[27] Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico-pathological parameters
Hedberg, Y
Roos, G
Ljungberg, B
Landberg, G
[J]. ACTA ONCOLOGICA, 2002, 41 (02) : 175 - 181
[28] Productive T-cell receptor beta-chain gene rearrangement: Coincident regulation of cell cycle and clonality during development in vivo
Hoffman, ES
Passoni, L
Crompton, T
Leu, TMJ
Schatz, DG
Koff, A
Owen, MJ
Hayday, AC
[J]. GENES & DEVELOPMENT, 1996, 10 (08) : 948 - 962
[29] Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293
[30] Ito Y, 2001, ANTICANCER RES, V21, P1043

← 1 2 3 4 5 6 7 →